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Abstract: Active drug efflux constitutes an important mechanism of antibiotic and multidrug 
resistance in bacteria. Understanding the distribution, expression, and physiological functions 
of multidrug efflux pumps, especially under physiologically and clinically relevant 
conditions of the pathogens, is the key to combat drug resistance. In animal hosts, most 
wounded, infected and inflamed tissues display low oxygen tensions. In this article, we 
summarize research development on multidrug efflux pumps in the medicinally relevant 
microaerobic and anaerobic pathogens and their implications in the effort to combat drug-
resistant infections. 
Keywords: multi-drug efflux pump; microaerobic bacteria; anaerobic bacteria; efflux  
pump inhibitors 
 
1. Introduction 
Since the first antibiotic, penicillin, was put into clinical practice in the early 20th century, hundreds 
of antibiotics have been developed and applied in clinical medicine. However, bacterial infectious diseases 
remain a major problem in public health [1]. An important reason for this ineptness is the emergence 
and prevalence of bacterial multidrug resistance (MDR). Thus far, four general strategies bacteria utilize to 
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develop resistance have been identified, prevention of drug entry, active drug efflux, modification of drug 
targets, and inactivation of drugs by hydrolyzation or enzymatic modification. Among them, active drug 
extrusion, which is carried out by a class of membrane proteins called multidrug efflux pumps, is the major 
reason for bacterial simultaneous resistance to multiple antibiotics, i.e., multidrug resistance, and is 
frequently associated with clinically isolated resistance [2,3]. To combat multidrug resistance, it is 
necessary to investigate the distribution, expression, and physiological functions of multidrug efflux 
pumps in bacteria, especially under the physiologically and medically relevant conditions. 
In animal hosts, most wounded, infected, and inflamed tissues display low oxygen tensions. Examples 
include inflamed gut, Schistosoma mansoni-infected tissue, Streptococcus pyogenes- and Leishmania 
amazonensis-infected skin, and Mycobacterium tuberculosis- or Aspergillus fumigatus-infected lung 
tissue [4]. In addition, facultative anaerobes including all major pathogens that infect the lower 
gastrointestinal (GI) tract constantly encounter oxygen fluctuations [5]. Although significant developments 
on the identification, expression, and physiological functions of bacterial multidrug efflux pumps under 
ordinary laboratory conditions and in model bacterial species have been achieved in the past decades, 
those in the physiologically and clinically relevant microaerobic and anaerobic niches of pathogens have 
not been extensively studied. In this article, we focus on the recent research development on bacterial 
multidrug efflux pumps in microaerobic and obligate anaerobic niches of pathogens (Table 1) and their 
implications in combating drug resistance. 
2. Classification of Efflux Pumps and Their Regulation 
Multidrug efflux pumps exist in almost all bacterial species. According to their different compositions, 
energy sources, substrates, and number of transmembrane domains, multidrug efflux pumps are divided 
into five classes: (i) the Major Facilitator Superfamily (MFS); (ii) the Resistance-Nodulation-Division 
(RND) family; (iii) the ATP-Binding Cassette (ABC) superfamily; (iv) the Small Multidrug Resistance 
(SMR) family; and (v) the Multidrug And Toxic compound Extrusion (MATE) family [1,6,7]. In addition 
to antibiotics, multidrug efflux pumps are also found to expel a broad range of environmental and 
physiological toxic compounds, such as dyes, detergents, bile acids, hormones, organic acids, etc. Thus, 
they are also referred to as xenobiotic pumps or transporters. 
Although ubiquitously encoded in bacterial genomes, except for a handful of housekeeping systems, 
the production levels of the majority of efflux pumps are low and their expression is often under the strict 
control of multiple regulators. Currently, efflux pump regulators are mainly categorized into three groups 
(Figure 1) [6]: (i) local repressors, which usually are located adjacent to the regulated efflux genes to 
repress their expression. They often belong to the MarR, MerR, or TetR transcription factor superfamily, 
such as AcrR, which represses the expression of acrAB in Salmonella [8–10]; (ii) global response 
regulators, which are often activated in response to certain stimuli and regulate a large scale of gene 
expression in addition to that of efflux pumps such as SoxS, which regulates acrAB expression in response 
to superoxide stress in Salmonella [11]; and (iii) two component systems (TCSs), which are consisted of 
a sensor kinase and a cognate response regulator. Examples include the BaeSR TCS, which activates the 
expression of mdtABCD [12,13]. All these three regulatory patterns which have been identified in the 
efflux pump expression in aerobic bacteria are also present in microaerobic and anaerobic pathogens.
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Table 1. A summary of the distribution, substrate spectrum, and regulation of bacterial efflux systems in microaerobic or anaerobic niches. 
Species Major Efflux Pumps Regulators Antimicrobial Agents Being Pumped Reference 
Microaerobic niches     
Campylobacter spp. CmeABC (RND) 
CmeR (TetR)  
CosR (OmpR) 
Ciprofloxacin, Norfloxacin, Cefotaxime, Fusidic Acid, Erythromycin [14–16] 
 CmeDEF (RND)  Ampicillin, Polymyxin B, Ethidium Bromide  [14] 
 CmeG (MFS)  
Ciprofloxacin, Erythromycin, Gentamicin, Tetracycline, Rifampicin, 
Ethidium Bromide, Cholic Acid, Hydrogen Peroxide 
[17] 
 
NhaA1/NhaA2 
(cation/proton antiporters) 
 Trisodium Phosphate [18] 
Helicobacter pylori HefABC (RND)  Metronidazole, Tetracycline, Erythromycin, Penicillin G, Ciprofloxacin [19,20] 
 HefDEF (RND)   [19] 
 HefGHI (RND)   [19] 
Staphylococcus 
aureus 
NorB MgrA (MarR) Moxifloxacin, Sparfloxacin [21] 
Anaerobic niches     
Bacteroides fragilis BmeABC1-16 (RND) BmeR (TetR) 
Cephems, Polypeptide Antibiotics, Fusidic Acid, Novobiocin, Puromycin  
Ampicillin, Cefoxitin, Cefoperazone, Ciprofloxacin, Metronidazole, 
Imipenem, Ethidium Bromide, Sodium Dodecyl Sulfate. 
[22,23] 
 BexA  Fluoroquinolone [24] 
Clostridium 
perfringens 
bcrABD bcrR Phenotypic Bacitracin [25] 
Escherichia coli MdtEF (RND) 
ArcAB  
(TCS)  
MnmE  
H-NS 
Indole Nitrosative Derivatives erythromycin [26,27] 
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Table 1. Cont. 
Species Major Efflux Pumps Regulators Antimicrobial Agents Being Pumped Reference 
 CusCBA (RND) CusSR (TCS) Cu(I) [28] 
Porphyromonas 
gingivalis 
XepCAB (RND)  
Rifampin, Puromycin,  
Ethidium Bromide 
[29] 
Salmonella enterica AcrAB (RND)   [30] 
 TolC   [31] 
 TetA  Etracycline, Ethidium Bromide [31] 
Staphylococcus 
aureus 
MnhF  Bile Salts [32] 
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Figure 1. Regulatory patterns of multidrug efflux pumps (using those in Salmonella 
typhimurium as an example). (a) Local repressor and global regulators: local regulator AcrR 
inhibits the expression of acrAB operon and global regulators MarA, SoxS, and Rob act as 
inducers of acrAB in response to different signals; (b) Two component system (TCS): BaeRS 
activates expression of the mdt operon, acrD, and tolC. Figures are adopted and modified 
based on those by Nishino et al. and Blair et al. [33,34]. 
3. Drug Efflux Pumps in Microaerobic Niches 
3.1. Campylobacter spp. Efflux Pumps 
Campylobacter spp. are the major foodborne, gram-negative, microaerophilic pathogens that  
can cause diarrhea, abdominal cramps, and fever in humans [35]. Antibiotics such as erythromycin  
or ciprofloxacin are utilized to treat severe cases, although the infections of Campylobacter are often 
clinically mild and self-limiting [36]. In the past decades, however, Campylobacter spp. Isolates, which 
display high tolerance to multiple antibiotics, have been isolated and the resistance was found to be 
largely achieved by multidrug efflux pumps [37]. 
CmeABC and CmeDEF are the two major RND efflux systems responsible for intrinsic resistance  
in Campylobacter jejuni (C. jejuni) (Table 1), the most common human pathogen among Campylobacter 
species. Both of them have been reported to contribute to the resistance of C. jejuni to various 
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antibiotics such as fluoroquinolones, macrolide, and tetracycline [14,38,39]. Expression of cmeABC was 
reported to be under the control of CmeR, a repressor belonging to the TetR family transcription factors. 
CmeR binds to the promoter region of cmeABC, specifically to the inverted repeat (IR) sequences, and 
represses its transcription. cmeR deletion mutant was shown to display high resistance to various 
antibiotics such as ciprofloxacin, norfloxacin, cefotaxime, erythromycin, and fusidic acid (two- to four-
fold in MICs) [15]. Another regulator named CosR, an OmpR-type oxidative stress response regulator, was 
also found to be a repressor of cmeABC, and cosR deletion also led to high transcriptional levels of 
cmeABC [16,40]. It has been found that the binding of CmeR to the promoter region of cmeABC can be 
inhibited by bile salts [41]. Since bile salts are the detergent molecules generated by the liver and secreted 
into the small intestine in the host that are harmful to bacteria, the increased cmeABC expression by bile 
salts not only promoted the survival of C. jejuni in the human intestinal tract but also led to enhanced 
resistance to multiple antibiotics [41,42]. Salicylate, which is often present in humans as the major 
metabolite of aspirin, a widely used medicine, was also reported to be able to induce the expression  
of cmeABC by inhibiting the function of CmeR in C. jejuni NCTC 11168 and cause resistance to 
fluoroquinolones [43,44]. 
In addition to CmeABC and CmeDEF, other efflux systems existing in C. jejuni were also found to 
contribute to antibiotic resistance (Table 1) [37]. For example, CmeG, a putative efflux pump of the 
MFS family, was found to be involved in antibiotic resistance and oxidative stress response in C. jejuni. 
A cmeG deletion mutant showed increased susceptibility to a broad range of antibiotics such as 
ciprofloxacin, erythromycin, gentamicin, tetracycline, etc. [17]. In addition, NhaA1/NhaA2 cation/proton 
antiporters and several as-yet uncharacterized RND multidrug efflux pumps were found to contribute to 
the tolerance of C. jejuni to sub-lethal concentrations of trisodium phosphate (TSP) [18], an 
antimicrobial agent that can disrupt the cytoplasmic and outer membranes of cells and is used frequently 
for food decontamination [45,46]. 
3.2. Helicobacter pylori Efflux Pumps 
Helicobacter pylori (H. pylori) is another common gram-negative, microaerophilic pathogen  
that inhabits the human stomach and duodenum [37]. H. pylori is associated with various diseases including 
chronic gastritis, peptic ulcers, low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma, 
noncardiac gastric adenocarcinoma, and other gut diseases [47]. Different kinds of antibiotics have been 
used to treat H. pylori infection. Among those, clarithromycin (CLR) was considered as the most common 
and effective drug. Unfortunately, antibiotic resistance is increasingly being identified in H. pylori and efflux 
pumps were reported to play an important role [48,49]. 
Studies revealed that H. pylori contains three putative RND efflux operons, namely hefABC, hefDEF, 
and hefGHI (Table 1) [19]. However, so far most studies have focused on hefA and hefC. An amoxicillin-
resistant Helicobacter hepaticus (H. hepaticus) strain demonstrated a bile salt-induced resistance profile 
similar to that which occurs in C. jejuni [41,50]. Such induction resulted in antibiotic resistance in  
H. hepaticus and its adaptation to the host intestinal tract [50]. In addition to bile salts, expression of hefA 
could also be induced by other antibiotics, resulting in efflux-mediated resistance to different antibiotics. For 
example, the relative expression level of hefA in chloramphenicol-induced H. pylori strains was found to be 
higher than that in the wild-type strain, and MICs of these strains to metronidazole, tetracycline, 
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erythromycin, penicillin G, and ciprofloxacin were significantly increased (≥four-fold) [20]. In another 
H. pylori strain that was exposed to metronidazole (Mtz), hefA expression was also induced significantly. 
This may explain the high Mtz resistance among clinical isolates of H. pylori due to the frequent 
application of Mtz in medicine [51]. H. pylori efflux pumps were also proposed to be involved in 
resistance to CLR, since the typical efflux pumps inhibitor (EPI) Phe-Arg β-naphthylamide 
dihydrochloride (PaβN) reduced the MIC of 14 out of 15 H. pylori strains analyzed to CLR with a four-fold 
or greater extent in the studies carried out by Kenro et al. [49]. Furthermore, it was found that biofilm 
could induce the expression of efflux pump genes and consequently enhance the resistance of  
H. pylori to CLR, since compared to the planktonic cells, a four-fold elevation of MIC to CLR was 
observed in H. pylori TK1402 biofilms [52]. Since biofilm of H. pylori has been detected in the gastric 
mucosa of certain patients infected with the pathogen [53], this result implied that specific efflux 
inhibition might need to be considered in the treatment of the infection. 
3.3. Staphylococcus aureus Efflux Pumps 
Staphylococcus aureus (S. aureus) is a gram-positive, facultative bacterium which can grow  
under oxygen-limited condition by fermentation or nitrate respiration [54]. It can cause a broad range of 
infectious diseases in humans, ranging from minor skin infections such as pimples, to life-threatening 
diseases such as pneumonia, toxic shock syndrome (TSS), blood infections, and sepsis. The emergence 
of antibiotic-resistant S. aureus pathogen, e.g., Methicillin-Resistant Staphylococcus aureus (MRSA), 
which is associated with increased expression of norA, has been a worldwide problem in clinical medicine. 
It was reported that in S. aureus N315, there are at least 30 genes encoding putative drug efflux pumps, 
and most of them are major facilitator superfamily (MFS) proteins (Table 1) [55]. 
Given that in hosts different infection sites have different oxygen tensions (for example, the abscess of 
skin infection can create completely anaerobic conditions), studies to examine gene expression changes  
in S. aureus under aerobic and anaerobic conditions have been conducted [54]. MgrA, a MarR family 
transcription factor, is a global regulator of S. aureus that negatively controls the expression of efflux 
pump genes norB and norC [56]. It was demonstrated that under reduced aeration, the dimeric DNA-binding 
form of MgrA was disrupted by posttranslational modification and only the monomeric form was 
observed. Consequently, norB transcription was de-repressed and the resistance of S. aureus to 
moxifloxacin and sparfloxacin (four-fold in MICs) was elevated [21]. Furthermore, deletion of mgrA 
was also found to promote the formation of biofilm [57], which might further enhance efflux-mediated 
multidrug resistance under anaerobic condition [52]. Under anaerobic conditions, it was reported that 
MnhF, a mammalian bile salt transporter homologue, was induced and contributed to the resistance of 
S. aureus to bile salts in the host [32]. mnhF deletion mutant led to decreased survival of S. aureus in an 
anaerobic three-stage continuous-culture model of the human colon (gut model) [32,58]. 
4. Drug Efflux Pumps in Anaerobic Niches 
Bacteroides fragilis (B. fragilis) is a common obligate anaerobe, which is usually considered as a friendly 
commensal in human. However, it is also the most commonly isolated anaerobic pathogen [59,60]. In 
recent years, increasing cases of MDR B. fragilis have been reported worldwide [61]. 
Antibiotics 2015, 4 386 
 
 
Among the different factors that cause multidrug resistance in B. fragilis, efflux pumps were proposed 
to be one of the culprits, because in the case of fluoroquinolones, treatment with efflux pump inhibitor 
carbonyl cyanide m-chlorophenylhydrazone (CCCP) led to a significant (five-fold) increase of 
ciprofloxacin accumulation in B. fragilis [62]. Subsequently, 16 homologues of P. aeruginosa  
MexAB-OprM system were identified in B. fragilis and named BmeABC1–16 (Table 1), where A, B, and 
C represent the membrane fusion protein, cytoplasmic efflux transporter protein, and outer membrane 
channel protein, respectively [22]. It was found that all 16 genes of bmeB1–16 were constitutively 
expressed in B. fragilis and at least seven efflux pumps were responsible for transporting antibiotics with 
overlapping substrates [63]. Using the BmeABC5 system as an example, BmeR5 was proposed as a TetR 
family regulator that could specifically bind to the bmeR5–bmeC5 intergenic region (IT1) to repress the 
expression of bmeABC5 operon [23]. A bmeR5 deletion mutation led to increased expression of bmeA5, 
bmeB5, and bmeC5, and two-fold increase in MICs to multiple chemicals such as ampicillin, cefoxitin, 
cefoperazone, ciprofloxacin, imipenem, metronidazole, ethidium bromide (EB), and sodium dodecyl sulfate 
(SDS) [23]. In addition to Bme, 7.5% of moxifloxacin-resistant B. fragilis strains isolated from different 
European countries were found to possess additional efflux pump BexA to extrude fluoroquinolone [24]. 
5. Physiological Roles of Efflux Pumps during the Anaerobic Adaptation of Facultative Bacteria 
Facultative bacterial pathogens can live under both low and high oxygen tensions and consequently 
are present in a broad range of human infections. Efflux systems in several of the model organisms  
in this group, such as Escherichia coli, Salmonella enterica serovar Typhimurium, Pseudomonas 
aeruginosa, etc., have been studied extensively. In this section, we focus on those efflux systems whose 
expression is altered in response to low oxygen tension in the anaerobic life style of these bacteria. 
5.1. Escherichia coli Efflux Pumps 
The model organism Escherichia coli (E. coli), a gram-negative facultative anaerobe, contains at least 
20 drug efflux systems [64]. Except for the housekeeping efflux pump AcrAB-TolC, expression of the 
rest of the efflux systems is low under ordinary laboratory conditions with sufficient oxygen. Studies from 
our group demonstrated that under anaerobic conditions, the typical environment of the human gut, 
expression of the RND efflux pump MdtEF was induced more than 20-fold and the induction was 
dependent on the anaerobic global regulator ArcA and a GTP binding protein MnmE [26,27]. It was 
shown that ArcA antagonized H-NS-mediated repression of the gadE-mdtEF operon and consequently 
increased its expression [27]. Interestingly, this anaerobically upregulated expression of MdtEF 
promoted the growth of E. coli during anaerobic respiration of nitrate by removing nitrosyl indole 
derivatives, a metabolic byproduct generated under this physiological condition, and simultaneously 
enhanced the resistance of E. coli to erythromycin and Rhodamine 6G [26]. 
In addition to antibiotics, metal ions represent another class of ancient antimicrobial agent and metal 
efflux systems are broadly distributed in bacterial genomes or plasmids. Recently, transition metals were 
also reported to act as an important immune defense strategy used by the animal host to combat  
pathogens [65]. For example, it was demonstrated that copper concentration was increased at pulmonary 
tissues infected by Mycobacterium tuberculosis (M. tuberculosis) [66]. Copper could also delay the growth 
of Rhodopseudomonas palustris TIE-1 under anaerobic conditions synergistically with iron [67]. In addition, 
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copper supplementation could protect dairy cattle from E. coli-induced mastitis [68]. In E. coli, copper 
can cause cellular toxicity by eliciting a Fenton reaction, which results in the production of Reactive 
Oxygen Species (ROS) and by damaging the iron–sulfur [Fe-S] cluster enzymes [65,69]. The RND pump 
CusCBA is dedicated to copper efflux in E. coli. Studies from our group have demonstrated that CusCBA 
was induced under anaerobic amino acid limited conditions without exogenous Cu supplement. The 
induced CusCBA protected Fe-S cluster enzymes and their biosynthesis to facilitate bacterial adaptation 
to this physiological condition and led to enhanced Cu and Ag tolerance in the bacterium under this 
condition [28]. 
5.2. Salmonella enterica Efflux Pumps 
Salmonella enterica serovar Typhimurium (S. enterica serovar Typhimurium) is a pathogen of 
human and animals that possesses nine potential drug transporters associated with drug resistance [70]. 
As in E. coli, AcrAB is the housekeeping RND family efflux pump that confers resistance to a variety 
of antibiotics, dyes, and detergents (Table 1) [71,72]. The AcrAB-TolC efflux pump has also been 
reported to be involved in invasion of host epithelial cells and macrophages  in vitro, and colonization 
of the bacterium in poultry [73]. Under aerobic conditions, it has been reported that several regulators 
including AcrR, MarA, SoxS, and RamA can regulate the expression of the AcrAB-TolC efflux  
pump [74–76]. Expression of the efflux systems under anaerobic conditions has not been studied. 
However, it was reported that under anaerobic conditions, deletion of acrA, acrB, and tolC affected 
transcription of 115, 569, and 171 genes, respectively, including those involved in pathogenicity, 
thereby indicating the relationship between anaerobic adaptation, antibiotics resistance, and 
pathogenicity [30]. It was also reported that expression of the multidrug efflux protein TolC and 
tetracycline efflux protein TetA were induced when S. enterica serovar Typhimurium CCARM 8009 
was exposed to bile salts under anaerobic conditions, which resulted in enhanced antibiotic resistance 
and pathogenesis [31]. 
5.3. Role of Efflux Pumps in the Anaerobic Niches of Bacterial Communities 
Another ecological and physiological environment with significant low oxygen tension is bacterial 
biofilm, which is defined as a matrix-enclosed bacterial population adherent to an abiotic or biotic 
surface [77]. Oxygen concentration decreases from the top of the biofilm to the bottom and this oxygen 
limitation in one species’ biofilm can promote the growth of other anaerobic bacteria when they coexist 
in the oxic areas of the host [78]. In the community of bacterial biofilms, a diverse range of metabolites 
are produced and secreted, including certain “antibiotics,” which belong to a class of microbial secondary 
metabolites produced by certain species but cytotoxic to the surrounding species. These “antibiotics” 
often have important physiological roles for those species that produce them [79]. For example, 
phenazines, a class of secondary metabolite produced primarily by the species of Pseudomonads, were 
recently found to play important roles in signaling, iron acquisition, community development, and 
anaerobic survival of P. aeruginosa [79–81]. Two such phenazine compounds, phenazine-1-carboxylic 
acid (PCA) and pyocyanin (PYO), have been shown to facilitate the biofilm formation and anaerobic 
growth of P. aeruginosa [82]. Although it has not been proved directly, efflux pumps are speculated to 
play a role in exporting these antibiotic phenazines out of producing cells, allowing their redox exchange 
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with extracellular compounds to promote electron shuttling and iron acquisition [81]. A promising efflux 
pump for this physiological role is the MexGHI-OpmD in P. aeruginosa PAO1 since genes encoding 
this system are located immediately downstream of the phenazine biosynthetic operon in the bacterium 
and their expression is induced by PYO [83]. 
6. Other Efflux Systems 
Expression of efflux pumps and their contribution to antibiotic resistance in the anaerobic niches of 
several other species have also been explored (Table 1). For instance, in the gram-negative pathogen 
Pseudomonas aeruginosa (P. aeruginosa), it was reported that anaerobic incubation increased MICs of 
the bacterium to tobramycin, amikacin, and aztreonam by approximately seven-, four-, and six-fold, 
respectively, compared to under aerobic condition [84], which was proposed to be mediated by efflux 
pump systems. Studies that analyzed the expression of the membrane fusion protein component of the 
RND efflux system under anaerobic condition proposed that anaerobiosis-induced antibiotic resistance 
might be due to the alteration of the expression of membrane fusion protein, which shifted the formation 
of RND efflux pumps to a dominance of the active MexEF-OprN pump [85]. In the dairy species 
Streptococcus thermophiles, the efflux pump TetA was reported to play a role in detoxification of several 
cytotoxic compounds, including tetracycline and ethidium bromide [86]. In Porphyromonas gingivalis, a 
gram-negative obligate anaerobe, a RND family efflux pump XepCAB was responsible for transporting 
multiple agents including rifampin, puromycin, and ethidium bromide and enhanced the resistance of the 
bacterium to these compounds [29]. In Clostridium perfringens, the bcrABD operon, together with its 
regulator bcrR, was shown to contribute to the resistance to bacitracin, which was confirmed by using 
EPI thioridazine [25]. Another obligate anaerobic pathogenic species, Prevotella spp., also contains RND 
family efflux pumps that enhance their resistance to tetracycline [87]. 
7. Inhibition of Drug Efflux in Microaerobic and Anaerobic Niches 
Considerable studies have demonstrated that bacterial multidrug efflux pumps play important roles 
in the drug resistance of pathogens in their microaerobic and anaerobic niches. Given that most infection 
sites in hosts are hypoxic [4], it is necessary to develop efflux pump inhibitors (EPIs) to restrain efflux 
activities under this physiological environment [88]. It was reported that C. jejuni NCTC11168 treated 
by PaβN decreased its resistance to trisodium phosphate (TSP) [18]. Given that CmeABC in C. jejuni 
mediates resistance to multiple drugs, inhibition of CmeABC using efflux pump inhibitor (EPI) PaβN 
serves as a potential means to decrease the efflux pump-associated antibiotic resistance [89]. EPIs have 
also been shown to be effective against multidrug-resistant H. pylori. It was demonstrated that antibiotic 
susceptibilities of a chloramphenicol-induced, hefA-dependent multidrug resistant H. pylori strain could 
be partially restored by carbonyl cyanide m-chlorophenyl hydrazone (CCCP) and pantoprazole, two 
different types of EPIs. A four- to 19-fold decrease in the MICs of a H. pylori strain to nine tested 
antibiotics such as erythromycin, ciprofloxacin, tetracycline, etc. was observed following the treatment 
of these two EPIs [90]. Recently, four chemicals from herbal extracts, namely emodin, baicalin, 
schizandrin, and berberine, were reported to reduce the resistance of H. pylori to amoxicillin and 
tetracycline (one- to two-fold) through inhibition of hefA expression [91], indicating a novel intervention 
in drug-resistant infections using natural products.  
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8. Conclusions 
Antibiotic resistance has been a public health threat worldwide. Drug efflux constitutes an important 
mechanism of multidrug resistance that is frequently isolated from clinical settings. In the past several 
decades, significant advancement in the distribution, expression, and substrate profiles of drug efflux 
pumps has been achieved [6]. However, less attention has been focused on the study of the pathogens 
present in microaerobic and strict anaerobic niches, which represent the conditions in wounded, infected, 
and inflamed tissues within a human host [4]. 
The fact that efflux genes ubiquitously exist in bacterial genomes prior to antibiotic development and 
application suggested that they have physiological functions and efflux-mediated drug resistance is 
perhaps merely a side effect of their over-expression under certain inducing conditions. Indeed, 
increasing evidence on the roles of efflux pumps in the general detoxification and physiological 
adaptation in bacteria has been reported in recent years. Specific physiological roles of efflux pumps in 
microaerobic and anaerobic pathogens are also starting to be revealed (Table 1). Understanding their 
regulation and physiological functions not only promotes our understanding of the emergence and 
prevalence of drug resistance but also their prediction and prevention. Furthermore, the role of efflux in 
bacterial communities represents an emerging research topic in the area, given that naturally produced 
antibiotics not only can inhibit bacterial growth but also can function as signals to affect the 
establishment and maintenance of community dynamics in complex environments, especially at low 
concentrations [92]. An interesting example is indole, a common secondary metabolite produced by E. coli 
recently found to be able to serve as a signal to turn on the efflux pumps of antibiotic-susceptible sister 
cells and promote the survival of the entire population [93]. Study of efflux pump expression in the 
context of populations such as in biofilms or polymicrobial communities, as well as in the presence of 
antibiotics, is necessary to explore their corresponding physiological significances. 
In recent decades, efflux pump inhibitors (EPIs) have emerged as a potential approach to circumvent 
efflux activities by means of energy supply disruption, antagonizing the substrate binding, substrates 
modification, etc. [88]. A number of EPIs have been intensively studied but no clinical EPIs are available 
currently [94]. In addition to EPIs, antibiotic drugs ineffectual against specific antibiotic-resistant pathogens 
could be considered as a second choice behind clearing other types of pathogens in order to preserve the 
current antibiotics pipeline. For example, fosfomycin and rifampin have been recently reported to have a 
better effect on eradicating H. pylori than CLR and Mtz, owing to their lower MICs [95]. Further studies 
on both the mechanisms of antibiotic resistance and the development of EPIs using synthetic tools and 
natural sources, especially under physiologically and clinically relevant conditions, are required to 
combat antibiotic and multidrug resistance. 
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